COMBIPRES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COMBIPRES (COMBIPRES).
Combipres is a fixed-dose combination of clonidine (alpha-2 adrenergic agonist) and chlorthalidone (thiazide-like diuretic). Clonidine stimulates alpha-2 receptors in the brainstem, reducing sympathetic outflow, leading to decreased peripheral vascular resistance, heart rate, and blood pressure. Chlorthalidone inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing sodium, chloride, and water excretion, reducing plasma volume and blood pressure.
| Metabolism | Clonidine is metabolized by the liver via cytochrome P450 enzymes, primarily CYP2D6, to inactive metabolites. Chlorthalidone is metabolized minimally; it is excreted largely unchanged in urine. |
| Excretion | Renal: clonidine 40-60% unchanged, chlorthalidone 50-70% unchanged; biliary/fecal: clonidine ~20% as metabolites, chlorthalidone minimal. |
| Half-life | Clonidine: 6-20 hours (mean 12 h) prolonged in renal impairment; chlorthalidone: 40-60 hours (mean 50 h) allowing alternate-day dosing. |
| Protein binding | Clonidine: 20-40% (albumin); chlorthalidone: 75% (albumin and erythrocytes). |
| Volume of Distribution | Clonidine: 2-3 L/kg (extensive tissue distribution); chlorthalidone: 3-4 L/kg (large Vd due to erythrocyte binding). |
| Bioavailability | Oral: clonidine 75-95% (immediate release), chlorthalidone ~65%. |
| Onset of Action | Oral: clonidine 30-60 min, chlorthalidone 2 hours; maximal effect clonidine 2-4 h, chlorthalidone 4-6 h. |
| Duration of Action | Clonidine: 6-12 hours (dose-dependent); chlorthalidone: 24-72 hours (enables once-daily dosing). |
1-2 tablets orally twice daily. Each tablet contains clonidine 0.1 mg and chlorthalidone 15 mg.
| Dosage form | TABLET |
| Renal impairment | Contraindicated for GFR <30 mL/min. For GFR 30-50 mL/min, reduce dose by 50% starting with 1 tablet daily. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: not recommended. |
| Pediatric use | Not recommended for use in pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | Initiate with 1 tablet daily; monitor for orthostatic hypotension and electrolyte imbalance. Avoid in frail elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COMBIPRES (COMBIPRES).
| Breastfeeding | Reserpine is excreted in breast milk; M/P ratio not reported. May cause infant bradycardia, respiratory depression, and hypotonia. Hydrochlorothiazide is excreted in small amounts; M/P ratio ~0.1-0.4. Due to reserpine's significant effects, breastfeeding is contraindicated while taking COMBIPRES. |
| Teratogenic Risk | COMBIPRES contains reserpine and hydrochlorothiazide. Reserpine: Crosses placenta; associated with increased risk of fetal respiratory depression, bradycardia, and hypothermia in neonates if used near term. Hydrochlorothiazide: Use in pregnancy may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Avoid in first trimester due to potential teratogenicity (neural tube defects and cardiovascular anomalies reported). Second and third trimester: Use only if clearly needed; may cause fetal and neonatal electrolyte disturbances. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to clonidine, chlorthalidone, or sulfonamide-derived drugs (chlorthalidone is a sulfonamide).","Anuria (due to chlorthalidone).","Severe renal impairment (eGFR <30 mL/min/1.73 m²) – use not recommended.","Hepatic coma or precoma (due to thiazide-like diuretics)."]
| Precautions | ["Rebound hypertension on abrupt discontinuation (clonidine component) – taper slowly.","Orthostatic hypotension, especially with chlorthalidone.","Electrolyte imbalances including hypokalemia, hyponatremia, and hypomagnesemia (chlorthalidone).","Renal impairment – monitor renal function.","Hepatic impairment – use with caution.","May cause drowsiness or dizziness – caution when driving or operating machinery."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, serum electrolytes (especially potassium and sodium), renal function, and fetal growth and well-being via ultrasound. Neonates should be monitored for bradycardia, respiratory depression, hypothermia, and electrolyte disturbances. |
| Fertility Effects | Reserpine may cause decreased libido and impaired sexual function in both sexes. Hydrochlorothiazide has no known direct effects on fertility. Overall, COMBIPRES may impair fertility via reserpine's effects on reproductive function. |